Securities code: Shenzhen Hepalink Pharmaceutical Group Co.Ltd(002399) securities abbreviation: Shenzhen Hepalink Pharmaceutical Group Co.Ltd(002399) Announcement No.: 2022017 Shenzhen Hepalink Pharmaceutical Group Co.Ltd(002399)
Announcement on the provision for asset impairment
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Shenzhen Hepalink Pharmaceutical Group Co.Ltd(002399) (hereinafter referred to as "the group") in accordance with the self regulatory guidelines for listed companies of Shenzhen Stock Exchange No. 1 - standardized operation of listed companies on the main board, the accounting standards for business enterprises and the relevant accounting policies of the group, in the process of preparing the company's financial statements for 2021, in order to truly and accurately reflect the assets and financial status of the group, for various accounts receivable According to the impairment test results of inventory and long-term assets, the corresponding impairment test is made for the assets as follows:
1、 Overview of the provision for asset impairment this time:
The group's asset items for which impairment provision is made in 2021 mainly include accounts receivable, other receivables, inventory and long-term equity investment. The total amount of impairment provision is RMB 35996844453. See the following table for details: unit: RMB
Accrued amount of the project in 2021
1、 Credit impairment loss
Including: impairment of accounts receivable 7185040054
Impairment of other receivables Acrobiosystems Co.Ltd(301080) 3867
2、 Asset impairment loss
Including: inventory impairment 3491838116
Impairment of long-term equity investment 22309162416
Total 35996844453
2、 The recognition standard and withdrawal method of the provision for asset impairment this time
(I) accounts receivable and other receivables
1. Accounting policy
In accordance with the provisions of accounting standards for Business Enterprises No. 22 - recognition and measurement of financial instruments, the group carries out impairment treatment and recognizes loss reserves for financial assets measured at amortized cost, debt instrument investments measured at fair value and whose changes are included in other comprehensive income on the basis of expected credit losses.
For receivables and contract assets without major financing components, the group uses a simplified measurement method to measure the loss reserves according to the amount equivalent to the expected credit loss in the whole duration.
For financial assets other than the above simplified measurement methods, the Group assesses whether their credit risk has increased significantly since the initial recognition on each balance sheet date. If the credit risk has not increased significantly since the initial recognition and is in the first stage, the group measures the loss reserve according to the amount equivalent to the expected credit loss in the next 12 months, and calculates the interest income according to the book balance and the actual interest rate; If the credit risk has increased significantly since the initial recognition, but there is no credit impairment, in the second stage, the group measures the loss provision according to the amount equivalent to the expected credit loss in the whole duration, and calculates the interest income according to the book balance and the effective interest rate; If credit impairment occurs after initial recognition, in the third stage, the group measures the loss provision according to the amount equivalent to the expected credit loss in the whole duration, and calculates the interest income according to the amortized cost and the effective interest rate. For financial instruments with only low credit risk on the balance sheet date, the group assumes that their credit risk has not increased significantly since initial recognition.
The Group assesses the expected credit loss of financial instruments based on individual and combination. Considering the credit risk characteristics of different customers, the group evaluates the expected credit loss of financial instruments such as accounts receivable and other accounts receivable based on the overdue aging combination.
When the group no longer reasonably expects to recover all or part of the contractual cash flow of financial assets, the group directly writes down the book balance of the financial assets.
2. Accrued amount
In 2021, the group recognized the impairment loss of accounts receivable of RMB 7185040054 (2020: RMB 1058918409) and the impairment loss of other accounts receivable of RMB Acrobiosystems Co.Ltd(301080) 3867 (2020: RMB 460463699). The provision of impairment loss is to evaluate the expected credit loss of accounts receivable and other receivables based on single and combination, taking into account the changes and characteristics of credit risk of different customers in the current period, and mainly evaluate the expected credit loss of accounts receivable and other receivables based on the overdue aging combination.
(II) inventory
1. Accounting policy
According to the provisions of accounting standards for Business Enterprises No. 1 - inventory, on the balance sheet date, the inventory of the group is measured according to the lower of cost and net realizable value. If the cost is higher than the net realizable value, the inventory falling price reserves are accrued and included in the current profits and losses.
Net realizable value refers to the amount of the estimated selling price of inventory minus the estimated cost to be incurred at the time of completion, estimated selling expenses and relevant taxes in daily activities. When the inventory falling price reserves are accrued, the raw materials are accrued by category, and the finished products are accrued by single item. For the inventories related to the product series produced and sold in the same region, with the same or similar end use or purpose, and it is difficult to measure separately from other items, the inventory falling price reserves shall be accrued jointly.
2. Accrued amount
In 2021, the group recognized the inventory falling price loss of RMB 3491838116 (2020: RMB 5587866008), which is mainly due to the fact that several batches of preparations exceed the validity period in this year and the net realizable value of several batches of trypsin API is lower than the cost due to the reduction of market price in the current period. (III) long term equity investment
1. Accounting policy
According to the provisions of accounting standards for Business Enterprises No. 8 - asset impairment, the group judges whether there are signs of possible impairment of assets on the balance sheet date. If there are signs of impairment, the group will estimate its recoverable amount and conduct impairment test.
The recoverable amount is determined according to the higher one between the net amount of the fair value of the asset minus the disposal expenses and the present value of the expected future cash flow of the asset. The group estimates its recoverable amount on the basis of individual assets; If it is difficult to estimate the recoverable amount of a single asset, the recoverable amount of the asset group shall be determined based on the asset group to which the asset belongs. The recognition of an asset group is based on whether the main cash inflow generated by the asset group is independent of the cash inflow of other assets or asset groups.
When the recoverable amount of an asset or asset group is lower than its book value, the group will write down its book value to the recoverable amount, the written down amount will be included in the current profit and loss, and the corresponding asset impairment provision will be withdrawn at the same time.
2. Accrued amount
In 2021, the group recognized the impairment loss of long-term equity investment of RMB 22309162416 (2020: none), which is due to the reduction of the market value of the associated company resver Logix Corp. and the poor financing situation affected by the capital market this year, as well as the difficulties encountered by Shenzhen Asia Pacific Health Management Co., Ltd. in this year, The impairment provision of RMB 18613894640 (2020: none) was made for the equity investment held by resver Logix Corp., and RMB 3695267776 (2020: none) was made for the equity investment held by Shenzhen Asia Pacific Health Management Co., Ltd.
3、 Impact of the current provision for asset impairment on the group
The provision for asset impairment accrued this time has a total impact on the group's pre tax profit of RMB 35996844453 in 2021.
It is hereby announced.
Shenzhen Hepalink Pharmaceutical Group Co.Ltd(002399) board of directors April 14, 2002
